---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-020108"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T16:23:16.527265+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Acura extends loan maturity and NDA deadline to May 31; warns of possible shutdown without new financing

## Summary
- Received $325k in new loans from AD Pharma in Feb 2025; total principal $7.49M at 5.25% interest.
- Maturity of secured note and warrant expiration extended from Feb 28 to May 31, 2025.
- LTX-03 NDA acceptance deadline extended to May 31, 2025; AD Pharma may terminate and take IP if not accepted.
- Without additional financing by mid-March 2025, company will scale back operations, furlough employees, or terminate operations.
- AD Pharma (controlled by John Schutte) owns ~65% of Acura's outstanding common stock.

## SEC filing metadata
- accession: 0001104659-25-020108
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465925020108/0001104659-25-020108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465925020108/tm254408d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-020108
- JSON: https://secwatch.observer/filing/0001104659-25-020108.json
- Plain text: https://secwatch.observer/filing/0001104659-25-020108.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of loans of $100,000, $100,000 and $125,000 with Abuse Deterrent Pharma, LLC at 5.25%.
  - Instrument: loan
  - Principal: loans of $100,000, $100,000 and $125,000
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Event: incurrence
  source text: On both February 28, 2025, February 14, 2025, and February 3, 2025, we received loans of $100,000, $100,000 and $125,000, respectively from Abuse Deterrent Pharma, LLC (“AD Pharma”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925020108/0001104659-25-020108-index.htm
- Debt Financings
  ACURA PHARMACEUTICALS, INC amended loan with Abuse Deterrent Pharma, LLC maturing May 31, 2025.
  - Instrument: loan
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Maturity: May 31, 2025
  - Event: amendment
  source text: This amendment #5 has an effective date of February 28, 2025 and changes the maturity date of the Amended Note from February 28, 2025 to May 31, 2025, at which time all principal and interest is due.
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465925020108/0001104659-25-020108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.